Global rates of influenza (FV) & pneumococcal (PV) vax in MM: Impact on HRU & OS [6/12/20] @mtmdphd et al. Abs EP967 #EHA25 https://t.co/lB14KmSH9S #mmsm #IDonc Infections cause of death in 7% / 15% / 20% / 40% of all pts who died in US / Europe / Latin America / Asia (P<0.0001) https://t.co/yHTHJdyR3p

Global rates of influenza (FV) & pneumococcal (PV) vax in MM: Impact on HRU & OS [6/12/20] @mtmdphd et al. Abs EP967 #EHA25 https://t.co/lB14KmSH9S #mmsm #IDonc Infections cause of death in: 19% (FV-) / 8% (FV+) pts (P=0.018); 19% (PV-) / 9% (PV+) pts (P=0.027)... https://t.co/BIKtztrUHU

Global rates of influenza (FV) & pneumococcal (PV) vax in MM: Impact on HRU & OS [6/12/20] @mtmdphd et al. Abs EP967 #EHA25 https://t.co/lB14KmSH9S #mmsm #IDonc Multivariate analysis - FV & PV significantly impacted OS when adjusted for age, region, and ECOG PS (Table) https://t.co/LlBSVrrcaT

Global rates of influenza (FV) & pneumococcal (PV) vax in MM Pts [6/12/20] @mtmdphd et al. Abs EP967 #EHA25 https://t.co/lB14KmSH9S #mmsm #IDonc n > 2500; 40%, (FV last yr) & 30% PV (prior 5yr) w/ FV: 56%/38%/27%/4% & PV: 43%/28%/21%/5% in US/Europe/Latin America/Asia https://t.co/hcewyN9lnc

Global rates of influenza (FV) and pneumococcal (PV) vaccination in multiple myeloma (MM) patients (Pts) in INSIGHT MM: Impact on healthcare resource utilization (HRU) and overall survival (OS) [6/12/20] @mtmdphd et al. Abstract EP967 #EHA25 https://t.co/lB14KmSH9S #mmsm #IDonc https://t.co/x9Y3PD5eHc

Global rates of influenza (FV) & pneumococcal (PV) vax in MM: Impact on HRU & OS [6/12/20] @mtmdphd et al. Abs EP967 #EHA25 https://t.co/lB14KmSH9S #mmsm #IDonc Infections cause of death in 7% / 15% / 20% / 40% of all pts who died in US / Europe / Latin America / Asia (P<0.0001) https://t.co/BMNeBMEkuJ

Global rates of influenza (FV) & pneumococcal (PV) vax in MM: Impact on HRU & OS [6/12/20] @mtmdphd et al. Abs EP967 #EHA25 https://t.co/lB14KmSH9S #mmsm #IDonc Infections cause of death in: 19% (FV-) / 8% (FV+) pts (P=0.018); 19% (PV-) / 9% (PV+) pts (P=0.027)... https://t.co/4EIneIfgxO

Global rates of influenza (FV) & pneumococcal (PV) vax in MM: Impact on HRU & OS [6/12/20] @mtmdphd et al. Abs EP967 #EHA25 https://t.co/lB14KmSH9S #mmsm #IDonc Multivariate analysis - FV & PV significantly impacted OS when adjusted for age, region, and ECOG PS (Table) https://t.co/UPteQBP5Di

Global rates of influenza (FV) & pneumococcal (PV) vax in MM Pts [6/12/20] @mtmdphd et al. Abs EP967 #EHA25 https://t.co/lB14KmSH9S #mmsm #IDonc n > 2500; 40%, (FV last yr) & 30% PV (prior 5yr) w/ FV: 56%/38%/27%/4% & PV: 43%/28%/21%/5% in US/Europe/Latin America/Asia https://t.co/xZQn4MR8xk

Global rates of influenza (FV) and pneumococcal (PV) vaccination in multiple myeloma (MM) patients (Pts) in INSIGHT MM: Impact on healthcare resource utilization (HRU) and overall survival (OS) [6/12/20] @mtmdphd et al. Abstract EP967 #EHA25 https://t.co/lB14KmSH9S #mmsm #IDonc https://t.co/8YNihh8BC9

Global rates of influenza (FV) & pneumococcal (PV) vax in MM: Impact on HRU & OS [6/12/20] @mtmdphd et al. Abs EP967 #EHA25 https://t.co/lB14KmSH9S #mmsm #IDonc Infections cause of death in: 19% (FV-) / 8% (FV+) pts (P=0.018); 19% (PV-) / 9% (PV+) pts (P=0.027)... https://t.co/47sHtyUKZB

Global rates of influenza (FV) & pneumococcal (PV) vax in MM: Impact on HRU & OS [6/12/20] @mtmdphd et al. Abs EP967 #EHA25 https://t.co/lB14KmSH9S #mmsm #IDonc Multivariate analysis - FV & PV significantly impacted OS when adjusted for age, region, and ECOG PS (Table) https://t.co/KOPNT5NF1k

Global rates of influenza (FV) & pneumococcal (PV) vax in MM Pts [6/12/20] @mtmdphd et al. Abs EP967 #EHA25 https://t.co/lB14KmB5Li #mmsm #IDonc n > 2500; 40%, (FV last yr) & 30% PV (prior 5yr) w/ FV: 56%/38%/27%/4% & PV: 43%/28%/21%/5% in US/Europe/Latin America/Asia https://t.co/C7taoD4mfT

Global rates of influenza (FV) and pneumococcal (PV) vaccination in multiple myeloma (MM) patients (Pts) in INSIGHT MM: Impact on healthcare resource utilization (HRU) and overall survival (OS) [6/12/20] @mtmdphd et al. Abstract EP967 #EHA25 https://t.co/lB14KmSH9S #mmsm #IDonc https://t.co/fwYIGi6YVW

Global rates of influenza (FV) & pneumococcal (PV) vax in MM: Impact on HRU & OS [6/12/20] @mtmdphd et al. Abs EP967 #EHA25 https://t.co/lB14KmSH9S #mmsm #IDonc Infections cause of death in 7% / 15% / 20% / 40% of all pts who died in US / Europe / Latin America / Asia (P<0.0001) https://t.co/otk5iZ8OFT

Global rates of influenza (FV) & pneumococcal (PV) vax in MM: Impact on HRU & OS [6/12/20] @mtmdphd et al. Abs EP967 #EHA25 https://t.co/lB14KmSH9S #mmsm #IDonc Infections cause of death in 7% / 15% / 20% / 40% of all pts who died in US / Europe / Latin America / Asia (P<0.0001) https://t.co/BYBVpDqCdS

Global rates of influenza (FV) & pneumococcal (PV) vax in MM: Impact on HRU & OS [6/12/20] @mtmdphd et al. Abs EP967 #EHA25 https://t.co/lB14KmSH9S #mmsm #IDonc Infections cause of death in: 19% (FV-) / 8% (FV+) pts (P=0.018); 19% (PV-) / 9% (PV+) pts (P=0.027)... https://t.co/mHLB4hwteY

Global rates of influenza (FV) & pneumococcal (PV) vax in MM: Impact on HRU & OS [6/12/20] @mtmdphd et al. Abs EP967 #EHA25 https://t.co/lB14KmSH9S #mmsm #IDonc Multivariate analysis - FV & PV significantly impacted OS when adjusted for age, region, and ECOG PS (Table) https://t.co/5P6jFQXOOl

Global rates of influenza (FV) & pneumococcal (PV) vax in MM Pts [6/12/20] @mtmdphd et al. Abs EP967 #EHA25 https://t.co/lB14KmSH9S #mmsm #IDonc n > 2500; 40%, (FV last yr) & 30% PV (prior 5yr) w/ FV: 56%/38%/27%/4% & PV: 43%/28%/21%/5% in US/Europe/Latin America/Asia https://t.co/PVQowIj2wy

Global rates of influenza (FV) and pneumococcal (PV) vaccination in multiple myeloma (MM) patients (Pts) in INSIGHT MM: Impact on healthcare resource utilization (HRU) and overall survival (OS) [6/12/20] @mtmdphd et al. Abstract EP967 #EHA25 https://t.co/lB14KmSH9S #mmsm #IDonc https://t.co/8oFvgpIn48

Global rates of influenza (FV) & pneumococcal (PV) vax in MM: Impact on HRU & OS [6/12/20] @mtmdphd et al. Abs EP967 #EHA25 https://t.co/lB14KmSH9S #mmsm #IDonc Infections cause of death in 7% / 15% / 20% / 40% of all pts who died in US / Europe / Latin America / Asia (P<0.0001) https://t.co/Nv7XyR5zdh

Global rates of influenza (FV) & pneumococcal (PV) vax in MM: Impact on HRU & OS [6/12/20] @mtmdphd et al. Abs EP967 #EHA25 https://t.co/lB14KmSH9S #mmsm #IDonc Infections cause of death in: 19% (FV-) / 8% (FV+) pts (P=0.018); 19% (PV-) / 9% (PV+) pts (P=0.027)... https://t.co/YUFvAZTvYl

Global rates of influenza (FV) & pneumococcal (PV) vax in MM: Impact on HRU & OS [6/12/20] @mtmdphd et al. Abs EP967 #EHA25 https://t.co/lB14KmSH9S #mmsm #IDonc Multivariate analysis - FV & PV significantly impacted OS when adjusted for age, region, and ECOG PS (Table) https://t.co/PXjV9tSWZs

Global rates of influenza (FV) & pneumococcal (PV) vax in MM Pts [6/12/20] @mtmdphd et al. Abs EP967 #EHA25 https://t.co/lB14KmSH9S #mmsm #IDonc n > 2500; 40%, (FV last yr) & 30% PV (prior 5yr) w/ FV: 56%/38%/27%/4% & PV: 43%/28%/21%/5% in US/Europe/Latin America/Asia https://t.co/2tXACWi9mp

Global rates of influenza (FV) and pneumococcal (PV) vaccination in multiple myeloma (MM) patients (Pts) in INSIGHT MM: Impact on healthcare resource utilization (HRU) and overall survival (OS) [6/12/20] @mtmdphd et al. Abstract EP967 #EHA25 https://t.co/lB14KmSH9S #mmsm #IDonc https://t.co/cViBr0qdIm

Global rates of influenza (FV) & pneumococcal (PV) vax in MM: Impact on HRU & OS [6/12/20] @mtmdphd et al. Abs EP967 #EHA25 https://t.co/lB14KmSH9S #mmsm #IDonc Infections cause of death in 7% / 15% / 20% / 40% of all pts who died in US / Europe / Latin America / Asia (P<0.0001) https://t.co/8afmGDPx1t

Global rates of influenza (FV) & pneumococcal (PV) vax in MM: Impact on HRU & OS [6/12/20] @mtmdphd et al. Abs EP967 #EHA25 https://t.co/lB14KmSH9S #mmsm #IDonc Infections cause of death in: 19% (FV-) / 8% (FV+) pts (P=0.018); 19% (PV-) / 9% (PV+) pts (P=0.027)... https://t.co/NoGQSfRleV

Global rates of influenza (FV) & pneumococcal (PV) vax in MM: Impact on HRU & OS [6/12/20] @mtmdphd et al. Abs EP967 #EHA25 https://t.co/lB14KmSH9S #mmsm #IDonc Multivariate analysis - FV & PV significantly impacted OS when adjusted for age, region, and ECOG PS (Table) https://t.co/xCZS2M22V6

Global rates of influenza (FV) & pneumococcal (PV) vax in MM Pts [6/12/20] @mtmdphd et al. Abs EP967 #EHA25 https://t.co/lB14KmSH9S #mmsm #IDonc n > 2500; 40%, (FV last yr) & 30% PV (prior 5yr) w/ FV: 56%/38%/27%/4% & PV: 43%/28%/21%/5% in US/Europe/Latin America/Asia https://t.co/EGlW0ZojX8

Global rates of influenza (FV) and pneumococcal (PV) vaccination in multiple myeloma (MM) patients (Pts) in INSIGHT MM: Impact on healthcare resource utilization (HRU) and overall survival (OS) [6/12/20] @mtmdphd et al. Abstract EP967 #EHA25 https://t.co/lB14KmSH9S #mmsm #IDonc https://t.co/mgZh8T930U

Global rates of influenza (FV) & pneumococcal (PV) vax in MM: Impact on HRU & OS [6/12/20] @mtmdphd et al. Abs EP967 #EHA25 https://t.co/lB14KmSH9S #mmsm #IDonc Infections cause of death in 7% / 15% / 20% / 40% of all pts who died in US / Europe / Latin America / Asia (P<0.0001) https://t.co/sAzwWLOfG4